JMKX005425

JMKX005425 is an orally administered small-molecule anticancer agent in early clinical development for the treatment of microsatellite instability-high (MSI-H) or mismatch repair–deficient (dMMR) advanced solid tumors.[1][3][4][5][14] It was initially developed by Shanghai Jiyu Pharmaceutical Technology and is being advanced clinically by Jiangxi Jemincare Group, with a first-in-human, open-label, multicenter phase 1 trial (NCT07208136) evaluating dose escalation and expansion in patients with MSI-H/dMMR advanced solid neoplasms.[1][3][5][11][14] The molecular target, detailed mechanism of action, and chemical structure remain undisclosed publicly, but the program is part of an oncology pipeline focused on treating advanced malignant solid neoplasms with high unmet need.[1][3][4][5][11][14]